Colorado tick fever (CTF) virus, a member of the family Reoviridae, genus Orbivirus, causes an illness in humans characterized by fever, headache, myalgia, lethargy, and other symptoms (5). Nearly 5,000 clinical cases of CTF have been reported to the Centers for Disease Control since 1961. The virus occurs commonly in the western United States and southwestern Canada, persisting in nature in a cycle involving Dermacentor andersoni ticks and a variety of small mammals (1). Diagnosis of CTF in humans has been most reliably established by isolation of the virus from the erythrocyte fraction of whole blood or by demonstrating the presence of viral antigen in the erythrocytes by the direct fluorescent-antibody technique (2). However, virus isolation and identification takes 1 to 2 weeks from the time of receipt of the specimen, the fluorescent-antibody technique requires special equipment that some laboratories do not possess, and interpretation of the results is subjective.
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Detection of antibody is also an adequate tool for diagnosing infection with this virus, but dependence on this method has several drawbacks. Complement fixation antibody titers usually are low, and about 25% of infected individuals do not develop a complement fixation antibody response (3) . The level of antibody detected by indirect fluorescent-antibody (IFA) and neutralization (N) tests rises earlier in the illness, but the presence of such antibodies can be considered only presumptive evidence for recent infections, as tests for them are routinely performed; to demonstrate a diagnostically significant change in antibody titer, sera must be obtained at least 1 Because enzyme immunoassays (EIAs) have recently been developed for an increasing number of arthropodborneand other viruses and since these tests can be used for rapid and specific detection of immunoglobulin M (IgM) and IgG produced in response to infections with these viruses, we considered it appropriate to determine the usefulness of EIAs for the serodiagnosis of CTF virus infections.
MATERIALS AND METHODS
Because our laboratories serve as primary reference diagnostic laboratories for CTF and other arthropod-borne viruses in the United States, a large collection of stored specimens was available for testing. We selected only paired and single sera from individuals from whom CTF virus had been isolated in suckling mice and identified by complement fixation tests or for whom a fourfold or greater rise in neutralizing antibody or vigorously, the fluids and debris were pooled, and the combined harvest was clarified by low-speed centrifugation, Virus in the supernatant fluid was pelleted at 39,000 rpm for 3 h at 4°C, and cell-associated virus was released from cell debris by sonication (cell lysate antigen). Both preparations were shown to have approximately equal titers by EIA, but clarified cell lysate was used as antigen in subsequent tests because of ease of preparation. Cell lysate antigen was taken up in phosphate-buffered saline (pH 7.2) and titrated by the EIA procedure outlined below. Unless otherwise noted, the diluent for all reagents was phosphate-buffered saline çon-taining 2% heat-inactivated fetal bovine serum. After addition and incubation of each reagent, the plates were washed four times with phosphate-buffered saline containing 0.05% Tween 20 and emptied manually. All reagents were added in 100-lil volumes.
EIA for detection of IgM antibody. Plates were coated with a 1:800 dilution of pretitrated goat anti-human ,u chainspçcific antibody (Cappel Laboratories, Malvern, Pa.) in carbonate buffer (pH 9.6) and allowed to incubate overnight at room temperature. A single 1:100 dilution of test serum was used for screening, and serial twofold dilutions of sera, beginning at 1:100, were used for titrations. These were incubated for 2 h at 38°C, sonicated CTF antigen diluted 1:300 was added, and the plates were incubated again, this time for 18 h at 4°C. Secondary antibody [pretitrated hyperimmune mouse ascitic fluid prepared to CTF (Florio) virus] diluted 1:300 was then added, and the plates were incubated for 1 h at 37°C. Horseradish peroxidaseconjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, Avondale, Pa.) was then added at a dilution of 1:2,000, and the plates were incubated again for 1 h at 37°C.
After a final series of washes, the 2,2'-azino-di-(3-ethylbenzthiazoline sulfonate) (ABTS) substrate (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) was added with 30% peroxide, and the plates were incubated at room temperature for 5 to 15 min, depending on the intensity of color (bluegreen) of the positive controls compared with that of the negative controls. Wells were read with a Titertek Multiskan (Eflab Oy, Helsinki, Finland) plate reader and a 405-nm filter; optical densities were recorded automatically. Controls included blanks, positive and negative sera, and wells with each reagent replaced by diluent; each test serum dilution was also tested with sonicated and clarified uninfected Vero cells (1:50). When the ratio of the optical density of the patient serum to the mean optical density of 40 normal sera (from individuals outside the CTF-endemic area and without neutralizing antibody to CTF virus) was .2.0, the serum was considered positive. All positive sera were retested to determine IgM antibody titers.
EIA for detection of IgG antibody. Plates were coated with sonicated and clarified cell lysate CTF virus antigen at a pretitrated dilution of 1:500 in carbonate buffer and incubated overnight at room temperature. The same dilutions of patient sera used for IgM antibody determinations were then added, the plates were incubated for 18 h at 4°C, and horseradish peroxidase-conjugated goat antibody to human IgG (Cappel Laboratories) was added. After an additional incubation for 1 h at 37°C, ABTS substrate was added, the plates were incubated, and optical densities were read as described above. Controls included positive and negative sera, wells with each reagent replaced by diluent, wells with no çoating antigen, and wells with normal Vero cell lysate (1:50). Ratios of optical densities of patient and normal sera of .2.0 were considered positive. All sera with IgG antibody at 1:100 were titrated. had IgM, IgG, and neutralizing antibodies (day 16). Thereafter, all sera had neutralizing antibody, 44 having IgM and 38 having IgG antibodies as well; 2 had only neutralizing antibody. IgM antibody to CTF virus was detected in one individual at 114 days after onset of illness and IgG antibody was found in another at 165 days after onset.
When log geometric mean titers of IgM, IgG, and neutralizing antibodies were plotted by time after onset of illness, it could be seen that production of neutralizing antibody closely paralleled but preceded that of IgM antibody until about 45 days after onset, when IgM antibody declined and both neutralizing and IgG antibody levels continued to rise (Fig. 1) .
DISCUSSION
That neutralizing antibody was found more often and sooner than IgM or IgG antibody is not surprising, since case and therefore specimen selection was based on previous determinations of neutralizing antibody or virus isolation. A more significant bias in testing might have been due to the serum dilutions used for preliminary screening tests (neutralizing antibody, 1:10; IgM and IgG antibodies, 1:100). Since lower dilutions of sera used for determining IgM (in particular) and IgG antibodies may lead to less specific test results, starting dilutions of 1:100 have advantages as well as drawbacks. IgM and IgG antibody titers of 1:100 were found in only four sera and one serum, respectively. It may be assumed that few sera would have had titers of 1:50. Moreover, the six sera with neutralizing antibody but not IgM or IgG antibody, which were collected 6, 9, 12, 13, 25, and 34 days after reported onset of illness, had titers of 10, 10, 10, .128, 160, and 1,280, respectively, the last three of which are comparatively high, given the absence of IgM and IgG antibodies.
A more significant bias might have been introduced by accepting the reported day of onset as invariably correct. However, this acceptance is within reason in such studies, and the resulting variation is accepted.
As determined by these studies, the test of choice for serodiagnosis of CTF virus infections, as far as sensitivity is concerned, is still the N test. Despite the fact that neutralizing antibody appears earliest and most often of the three, the test is time consuming (about a week) It is well recognized that CTF virus may be isolated from infected humans and experimentally infected animals for 1 to 3 months or more after onset of symptoms and that antigenemia may persist for an additional month (4) (5) (6) . It has been shown that CTF virus replicates in hemopoietic tissues of liver, spleen, and bone marrow, is found in plasma usually for only a week, and then, probably as a result of increasing humoral antibody, is localized in erythroblasts, reticulocytes, and erythrocytes (4, 8) . Virus replication in lymphoid tissues may be related to the slow development of detectable antibodies in humans. The development of a test for detection of circulating CTF virus or antigen could obviate antibody testing. Given that CTF is a disease with an approximate mean incubation period of 4 days, prolonged morbidity (1 to 3 weeks), and prolonged viremia or antigenemia, such a test, if sufficiently rapid and sensitive, would replace other tests in current usage.
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